XML 53 R36.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Segment Information (Tables) | 12 Months Ended
--- | ---
Jun. 30, 2024
Notes Tables |
Schedule of financial information by reportable segment | Following is financial information relating to the operating segments (in thousands):
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Year Ended June 30,
​ |  | 2024 |  | 2023 |  | 2022
Net sales: |  | ​ |  | ​ | ​ | ​ | ​ | ​ | ​
Protein Sciences | ​ | $ | 830,902 |  | $ | 845,747 | ​ | $ | 832,311
Diagnostics and Genomics | ​ |  | 326,392 | ​ |  | 292,602 | ​ |  | 274,843
Other revenue(1) | ​ | ​ | 4,153 | ​ | ​ | — | ​ | ​ | —
Intersegment | ​ |  | (2,387) | ​ |  | (1,647) | ​ |  | (1,555)
Consolidated net sales | ​ | $ | 1,159,060 |  | $ | 1,136,702 | ​ | $ | 1,105,599
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating income: | ​ |  |  | ​ |  |  | ​ |  |
Protein Sciences | ​ | $ | 354,775 |  | $ | 373,684 | ​ | $ | 377,623
Diagnostics and Genomics | ​ |  | 24,546 | ​ |  | 43,037 | ​ |  | 48,977
Segment operating income | ​ |  | 379,321 | ​ |  | 416,721 | ​ |  | 426,600
Costs recognized on sale of acquired inventory | ​ |  | (729) | ​ |  | (400) | ​ |  | (1,596)
Amortization of intangibles | ​ |  | (78,318) | ​ |  | (76,413) | ​ |  | (73,054)
Impact of partially-owned consolidated subsidiaries(2) | ​ |  | — | ​ |  | 647 | ​ |  | (2,393)
Acquisition related expenses and other | ​ |  | (6,980) | ​ |  | 9,965 | ​ |  | 19,070
Certain Litigation Charges | ​ | ​ | (3,506) | ​ | ​ | — | ​ | ​ | —
Impairment of assets held-for-sale | ​ | ​ | (21,963) | ​ | ​ | — | ​ | ​ | —
Eminence impairment | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (18,715)
Stock based compensation, inclusive of employer taxes | ​ |  | (40,277) | ​ |  | (41,217) | ​ |  | (46,401)
Restructuring and restructuring-related costs | ​ |  | (12,245) | ​ |  | (3,829) | ​ |  | (1,640)
Corporate general, selling, and administrative expenses | ​ |  | (9,142) | ​ |  | (6,530) | ​ |  | (5,281)
Impact of business held-for-sale(1) | ​ | ​ | 525 | ​ | ​ | — | ​ | ​ | —
Consolidated operating income | ​ | $ | 206,686 |  | $ | 298,944 | ​ | $ | 296,590
| (1) | Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. For the year ended June 30, 2024, includes the six-month results of this business held-for-sale for the period starting December 31, 2023 through June 30, 2024 while the business has met the held-for-sale criteria.
| (2) | Includes the annual results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party in the first fiscal quarter of 2023.
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Year Ended June 30,
​ |  | 2024 |  | 2023 |  | 2022
Consumables revenue - Protein Sciences | ​ | $ | 657,679 | ​ | $ | 665,301 | ​ | $ | 646,952
Consumables revenue - Diagnostics and Genomics | ​ |  | 266,348 | ​ |  | 252,432 | ​ |  | 243,922
Consumables revenue - Other revenue(1) | ​ | ​ | 4,153 | ​ | ​ | — | ​ | ​ | —
Total consumable revenue | ​ | $ | 928,180 | ​ | $ | 917,733 | ​ | $ | 890,874
​ (1)Includes the results of a business that has met the held-for-sale criteria since December 31, 2023. ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Year ended June 30,
​ |  | 2024 |  | 2023
Long-lived assets: | ​ | ​ | ​ | ​ | ​ | ​
United States and Canada | ​ | $ | 211,597 |  | $ | 203,657
Europe |  |  | 27,862 | ​ |  | 19,263
Asia | ​ |  | 11,695 | ​ |  | 3,280
Total long-lived assets | ​ | $ | 251,154 |  | $ | 226,200
Intangible assets: | ​ |  |  | ​ |  |
United States and Canada | ​ | $ | 443,740 |  | $ | 529,652
Europe | ​ |  | 63,138 | ​ |  | 4,553
Asia | ​ |  | 203 | ​ |  | 440
Total intangible assets | ​ | $ | 507,081 |  | $ | 534,645

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration